Mounjaro 2.5 mg: Impact on Gastric Emptying Rate in T2D Patients Mounjaro 2.5 mg (tirzepatide) significantly affects gastric emptying rate, especially during the initial weeks of treatment. As a dual GIP/GLP-1 receptor agonist, it slows how quickly food leaves the stomach. For patients with Type 2 Diabetes (T2D), this delayed gastric emptying helps improve post-meal glucose control, reduce appetite, and support early weight loss. The effect is typically strongest after the first dose and gradually becomes less pronounced over time as the body adapts. However, some patients may still experience slower digestion, leading to symptoms like bloating, nausea, early fullness, or mild reflux. Overall, Mounjaro 2.5 mg improves blood sugar stability by reducing glucose spikes after meals while contributing to appetite control—making it an effective starter dose for T2D management. Visit : https://buymedlife.com/mounjaro-kwikpen-2-5mg